TNFRSF17 and plasma cell myeloma: Particularly, the development of CAR-T cells targeting the B cell maturation antigen (BCMA) has demonstrated remarkable efficacy in treating patients with relapsed/refractory multiple myeloma (RRMM), offering unprecedented response rates and opening new avenues for remission [26–28].